Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Allogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
-
State-of-the-Art Manufacturing Facility to be Located in the San Francisco East Bay AreaAllogene Committed to Advanced Cell Manufacturing for Long-Term Clinical and Commercial AlloCAR T™ Production ...
-
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
-
Allogene to Initiate the ALPHA Study for ALLO-501 in Relapsed/Refractory Non-Hodgkin LymphomaALLO-647, Allogene’s Proprietary anti-CD52 Antibody, Will be Administered as Part of the Lymphodepletion...
-
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
-
82 percent of Patients Achieved a Complete Remission when Lymphodepletion Regimen Included an anti-CD52 Monoclonal Antibody (mAb)Safety Profile of UCART19 Appears Manageable with No Evidence of...
-
Preclinical Data Supports Advancement of ALLO-715 into Phase 1 in Multiple MyelomaALLO-715 Investigational New Drug Application and Initiation of a Phase 1 Trial Planned for 2019 SOUTH SAN FRANCISCO,...
-
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...